BIOMARCARE - Biomarker for Cardiovascular Risk Assessment in Europe / Edukad projektid

programme [ FP7 ] search term [ HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH ]

« back to search results page

Biomarker for Cardiovascular Risk Assessment in Europe

acronym:	BIOMARCARE
start:	2011-10-01
end:	2015-09-30

programme:	FP7 - Euroopa Liidu 7. raamprogramm
sub-programme:	HEALTH - Tervis
instrument:	CP-FP - Väikese- ja keskmisemahulised koostööprojektid
call identifier:	FP7-HEALTH-2011-two-stage
project number:	278913
duration in months:	48
partner count:	29

abstract:	Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role in the drive towards personalised medicine remains uncertain. Based on harmonised and standardised European population cohorts we have built significant research collaboration, expertise and infrastructure in the EU. We will apply highly innovative SME-driven technologies and perform large-scale biomarker determination to assess the predictive value of existing and emerging biomarkers. Selection of emerging biomarkers will be based on integrated cutting-edge quantitative proteomic, transcriptomic, metabolomic, and miRNomic datasets established by private and public consortium members that will be disclosed to this consortium. Existing biomarkers will be selected based on non-redundancy and their association with cardiovascular risk and phenotypes. After SME-guided development of innovative assay systems biomarkers will be tested and validated in a stepwise fashion among European populations in primary and secondary prevention. In addition to their impact on risk prediction, their association with lifestyle determinants and cardiovascular phenotypes assessed by ultrasound and MRI technique will be evaluated. We will establish a BiomarCaRE panel which leads to improved disease prediction among different European populations. International collaborations with world-class clinical trial investigators will add data on the interaction of the BiomarCaRE panel with risk-lowering medication and lifestyle changes. The outcome of SME-driven technology development and clinical validation will undergo a medical technology assessment. The determination of cost-effectiveness will guide further clinical evaluation. These studies will reveal new methods of improved cardiovascular risk estimation and will open the path towards personalised medicine.

partner no and role		partner name	country	contact person	web page
1	coordinator	UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF	DE	Tanja Zeller	http://www.uke.uni-hamburg.de
2	partner	TERVEYDEN JA HYVINVOINNIN LAITOS	FI	Kari Kuulasmaa	http://www.thl.fi
3	partner	CAVADIS BV	NL	Heico Breek	http://www.cavadis.com
4	partner	UNIVERSITAIR MEDISCH CENTRUM UTRECHT	NL	Gerard Pasterkamp	http://www.umcutrecht.nl
5	partner	HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH	DE	Jürgen Ertel	http://www.helmholtz-muenchen.de
6	partner	BIOCRATES LIFE SCIENCES AG	AT	Markus Speiser	http://www.biocrates.com
7	partner	UNIVERSITAET ZU LUEBECK	DE	Gabriele Schatton	http://www.uni-luebeck.de
8	partner	UMIT- PRIVATE UNIVERSITAT FUER GESUNDHEITSWISSENSCHAFTEN, MEDIZINISCHEINFORMATIK UND TECHNIK GMBH	AT	Petra Schnell-Inderst
9	partner	MEDIZINISCHE HOCHSCHULE HANNOVER	DE	Frank Dittrich	http://www.mh-hannover.de
10	partner	FLEET BIOPROCESSING LIMITED	UK	Adrian Wilkinson	http://www.fleetbioprocessing.co.uk
11	partner	BIOCARTIS SA	CH	Patrick Van Den Bogaard	http://www.biocartis.com
12	partner	RESEARCH NETWORK SERVICES LIMITED	UK	Erik Werner	http://www.rns4u.com
13	partner	UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ	DE	Uta Veith	http://www.um-mainz.de/
14	partner	UNIVERSITETET I TROMSOE	NO	Anne Fismen	http://uit.no/
15	partner	UNIVERSITA CATTOLICA DEL SACRO CUORE	IT	Filippo Leone	http://www.unicattolica.it
16	partner	ERNST-MORITZ-ARNDT-UNIVERSITÄT GREIFSWALD	DE	Andrea Völker
17	partner	UNIVERSITY COLLEGE LONDON	UK	Gerta Borg-Carbott	http://www.ucl.ac.uk
18	partner	QUEEN'S UNIVERSITY BELFAST	UK	Colleen Spence	http://www.qub.ac.uk
19	partner	INSTITUT PASTEUR DE LILLE FONDATION	FR	Fabienne Jean	http://www.pasteur-lille.fr
20	partner	CONSORCI INSTITUT CATALÀ DE CIÈNCIES CARDIOVASCULARS	ES	Joaquim Escobar	http://en.iccc.cat
21	partner	UMEA UNIVERSITET	SE	Lars Wikman	http://www.umu.se
22	partner	Tartu Ülikool	EE	Merike Leego	http://www.ut.ee
23	partner	REGION HOVEDSTADEN	DK	Gitte Fogelberg	http://www.regionh.dk
24	partner	UNIVERSITA DEGLI STUDI DELL'INSUBRIA	IT	Giovanni Barbieri	http://www.uninsubria.it
25	partner	UNIVERSITY OF DUNDEE	UK	Jim Mcgregor	http://www.dundee.ac.uk
26	partner	UNIVERSITAETSSPITAL BASEL	CH	Thomas Gruberski
27	partner	UNIVERSITAET ULM	DE	Frank Gleixner
28	partner	HAMILTON HEALTH SCIENCES CORPORATION	CA	Beena Cracknell
29	partner	THE UNIVERSITY OF SYDNEY	AU	Kate Taylor	http://www.usyd.edu.au/